|
KMID : 1148920190530020096
|
|
Nuclear Medicine and Molecular Imaging
2019 Volume.53 No. 2 p.96 ~ p.101
|
|
|
Current Status and Growth of Nuclear Theranostics in Singapore
|
|
Huang Hian Liang
Tong Aaron Kian Ti
Thang Sue Ping
Yan Sean Xuexian
Lam Winnie Wing Chuen
Loke Kelvin Siu Hoong
Tang Charlene Yu Lin
Cheng Lenith Tai Jit
Ooi Gideon Su Kai
Low Han Chung
Magsombol Butch Maulion
Tham Wei Ying
Goh Charles Xian Yang
Tan Colin Jingxian
Khor Yiu Ming
Zaheer Sumbul
Bharadwaj Pushan
Xie Wanying
Ng David Chee Eng
|
|
|
Abstract
|
|
|
|
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
|
|
|
KEYWORD
|
|
|
Theranostic, Singapore, Radioiodine, Lutetium, Yttrium, Radium
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|